Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Alternate vs Commercial Ixekizumab in Healthy Subjects
NCT04259346Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ixekizumab in plaque psoriasis (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Ixekizumab, Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measured Concentration and 1 more. Started Feb 2020; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04259346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04259346.